Thomas Müller

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 28

Top Topics

Peritoneal Dialysis

Ejection Fraction

Top Venues

Journal of neural transmission (Vienna, Austria : 1996)

Expert review of clinical pharmacology

Movement disorders : official journal of the Movement Disorder Society

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Müller, Carsten Buhmann, Martin Delf, Fabian Klostermann, Andreas Kupsch, Axel Lipp, Martina Müngersdorf, Wolfram von Pannwitz, Martin Südmeyer
Clinicians' viewpoints on current paradigms of care and research in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996) (2024)
Thomas Müller, Wilfried Kuhn
Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 38 (4) (2023)
Thomas Müller, Wilfried Kuhn
Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease. Clinical neuropharmacology 46 (5) (2023)
Thomas Müller, Peter Riederer, Wilfried Kuhn
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome? Expert review of clinical pharmacology 16 (2) (2023)
Thomas Müller, Wilfried Kuhn
An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 38 (12) (2023)
Thomas Müller
The role of istradefylline in the Parkinson's disease armamentarium. Expert opinion on pharmacotherapy (2023)
Thomas Müller, Peter Riederer, Wilfried Kuhn
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome? Expert review of clinical pharmacology (2023)
Thomas Müller
DNL151, DNL201 and BIIB094: experimental agents for the treatment of Parkinson's disease. Expert opinion on investigational drugs (2023)
Thomas Müller, Wilfried Kuhn
An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society 38 (12) (2023)
Thomas Müller, Peter Riederer
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996) (2023)
Thomas Müller, Peter Riederer, Wilfried Kuhn
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome? Expert review of clinical pharmacology (2023)
Thomas Müller, Peter Riederer, Wilfried Kuhn
Aminoadamantanes: from treatment of Parkinson's and Alzheimer's disease to symptom amelioration of long COVID-19 syndrome? Expert review of clinical pharmacology 16 (2) (2023)
Thomas Müller
Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson's disease: are we on the right track? Expert review of molecular diagnostics 22 (4) (2022)
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. Cells 11 (9) (2022)
Thomas Müller
What are the main considerations when prescribing pharmacotherapy for Parkinson's disease? Expert opinion on pharmacotherapy 23 (7) (2022)
Wilfried Kuhn, Georg Karp, Thomas Müller
No Vitamin D Deficiency in Patients with Parkinson's Disease. Degenerative neurological and neuromuscular disease 12 (2022)
Thomas Müller
GOCOVRI ® (amantadine) extended-release capsules in Parkinson's disease. Neurodegenerative disease management 12 (1) (2021)
Thomas Müller, Wilfried Kuhn
Complex motion series performance differs between previously untreated patients with Parkinson's disease and controls. Journal of neural transmission (Vienna, Austria : 1996) (2021)
Thomas Müller, Bernhard Klaus Mueller, Peter Riederer
Perspective: Treatment for Disease Modification in Chronic Neurodegeneration. Cells 10 (4) (2021)
Thomas Müller
Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence. Journal of experimental pharmacology 13 (2021)
Thomas Müller
View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track? Biologics : targets & therapy 15 (2021)
Thomas Müller, Lutz Lohse, Andreas Blodau, Katja Frommholz
Vitamin D and Blood Parameters. Biomolecules 11 (7) (2021)
Thomas Müller, Ali Harati
Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996) 127 (10) (2020)
Wilfried Kuhn, Tanja Neufeld, Thomas Müller
Kinesiology training in patients with Parkinson's disease: results of a pilot study. Journal of neural transmission (Vienna, Austria : 1996) 127 (5) (2020)
Thomas Müller, Ali Harati
Different response to instrumental tests in relation to cognitive demand after dopaminergic stimulation in previously treated patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996) 127 (2) (2020)
Thomas Müller
Safinamide in the treatment of Parkinson's disease. Neurodegenerative disease management 10 (4) (2020)
Thomas Müller
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease. Expert opinion on pharmacotherapy 21 (14) (2020)
Thomas Müller, Lutz Lohse, Andreas Blodau, Katja Frommholz
Vitamin D rise enhances blood perfusion in patients with multiple sclerosis. Journal of neural transmission (Vienna, Austria : 1996) 126 (12) (2019)